These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 28385665)

  • 21. Clinical Epigenetics of Neuroendocrine Tumors: The Road Ahead.
    Colao A; de Nigris F; Modica R; Napoli C
    Front Endocrinol (Lausanne); 2020; 11():604341. PubMed ID: 33384663
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic relevance of aberrant DNA methylation in g1 and g2 pancreatic neuroendocrine tumors.
    Stefanoli M; La Rosa S; Sahnane N; Romualdi C; Pastorino R; Marando A; Capella C; Sessa F; Furlan D
    Neuroendocrinology; 2014; 100(1):26-34. PubMed ID: 25011998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. DNA methylation profiling in MEN1-related pancreatic neuroendocrine tumors reveals a potential epigenetic target for treatment.
    Conemans EB; Lodewijk L; Moelans CB; Offerhaus GJA; Pieterman CRC; Morsink FH; Dekkers OM; de Herder WW; Hermus AR; van der Horst-Schrivers AN; Drent ML; Bisschop PH; Havekes B; Brosens LAA; Dreijerink KMA; Borel Rinkes IHM; Timmers HTM; Valk GD; Vriens MR
    Eur J Endocrinol; 2018 Sep; 179(3):153-160. PubMed ID: 29903750
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential.
    Camilli M; Papadimitriou K; Nogueira A; Incorvaia L; Galvano A; D'Antonio F; Ferri J; Santini D; Silvestris N; Russo A; Peeters M; Rolfo C
    Expert Rev Gastroenterol Hepatol; 2018 May; 12(5):471-478. PubMed ID: 29629846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High VEGF serum values are associated with locoregional spread of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
    Cigrovski Berković M; Čačev T; Catela Ivković T; Marout J; Ulamec M; Zjačić-Rotkvić V; Kapitanović S
    Mol Cell Endocrinol; 2016 Apr; 425():61-8. PubMed ID: 26805636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cancer. New epigenetic drivers of cancers.
    Elsässer SJ; Allis CD; Lewis PW
    Science; 2011 Mar; 331(6021):1145-6. PubMed ID: 21385704
    [No Abstract]   [Full Text] [Related]  

  • 27. Application of multiomics sequencing and advances in the molecular mechanisms of pancreatic neuroendocrine neoplasms.
    Jiang R; Hong X; Zhao Y; Wu W
    Cancer Lett; 2021 Feb; 499():39-48. PubMed ID: 33246093
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Integrated clinicopathological features and gene microarray analysis of pancreatic neuroendocrine tumors.
    Zhou H; Chen Q; Tan W; Qiu Z; Li S; Song Y; Gao S
    Gene; 2017 Aug; 625():72-77. PubMed ID: 28479381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Detection of Somatic Mutations in Gastroenteropancreatic Neuroendocrine Tumors Using Targeted Deep Sequencing.
    Backman S; Norlén O; Eriksson B; Skogseid B; Stålberg P; Crona J
    Anticancer Res; 2017 Feb; 37(2):705-712. PubMed ID: 28179320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mammalian target of rapamycin signaling activation patterns in pancreatic neuroendocrine tumors.
    Komori Y; Yada K; Ohta M; Uchida H; Iwashita Y; Fukuzawa K; Kashima K; Yokoyama S; Inomata M; Kitano S
    J Hepatobiliary Pancreat Sci; 2014 Apr; 21(4):288-95. PubMed ID: 24002888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [What is new in the pathology of pancreatic neuroendocrine tumors?].
    Komminoth P; Perren A
    Pathologe; 2015 May; 36(3):220-8. PubMed ID: 25941099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetics of pancreatic neuroendocrine tumors: implications for the clinic.
    Pea A; Hruban RH; Wood LD
    Expert Rev Gastroenterol Hepatol; 2015; 9(11):1407-19. PubMed ID: 26413978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic landscape of pancreatic neuroendocrine tumors.
    Gebauer N; Schmidt-Werthern C; Bernard V; Feller AC; Keck T; Begum N; Rades D; Lehnert H; Brabant G; Thorns C
    World J Gastroenterol; 2014 Dec; 20(46):17498-506. PubMed ID: 25516664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumour biology of gastroenteropancreatic neuroendocrine tumours.
    Grötzinger C
    Neuroendocrinology; 2004; 80 Suppl 1():8-11. PubMed ID: 15477708
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequent silencing of RASSF1A by DNA methylation in thymic neuroendocrine tumours.
    Kajiura K; Takizawa H; Morimoto Y; Masuda K; Tsuboi M; Kishibuchi R; Wusiman N; Sawada T; Kawakita N; Toba H; Yoshida M; Kawakami Y; Naruto T; Imoto I; Tangoku A; Kondo K
    Lung Cancer; 2017 Sep; 111():116-123. PubMed ID: 28838380
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genome-wide DNA methylation analysis reveals molecular subtypes of pancreatic cancer.
    Mishra NK; Guda C
    Oncotarget; 2017 Apr; 8(17):28990-29012. PubMed ID: 28423671
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pancreatic neuroendocrine tumors: pathologic and molecular characteristics.
    Shi C; Klimstra DS
    Semin Diagn Pathol; 2014 Nov; 31(6):498-511. PubMed ID: 25441311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetic associations with neuroendocrine tumor risk: results from a genome-wide association study.
    Du Y; Ter-Minassian M; Brais L; Brooks N; Waldron A; Chan JA; Lin X; Kraft P; Christiani DC; Kulke MH
    Endocr Relat Cancer; 2016 Aug; 23(8):587-94. PubMed ID: 27492634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Road to early detection of pancreatic cancer: Attempts to utilize epigenetic biomarkers.
    Fukushige S; Horii A
    Cancer Lett; 2014 Jan; 342(2):231-7. PubMed ID: 22450751
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiopoietin-2 promotes disease progression of neuroendocrine tumors.
    Detjen KM; Rieke S; Deters A; Schulz P; Rexin A; Vollmer S; Hauff P; Wiedenmann B; Pavel M; Scholz A
    Clin Cancer Res; 2010 Jan; 16(2):420-9. PubMed ID: 20068079
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.